It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
scientific solutions | protein science & structural biology
Macromolecular NMR
At Sygnature Discovery, NMR enables the exploration of interactions, structure, and dynamics of macromolecules in solution –delivering high quality insights that accelerate drug discovery programmes
NMR exploits the magnetic properties of atomic nuclei – most commonly hydrogen (1H), carbon (13C), nitrogen (15N), and phosphorus (31P) – to provide precise insights into the structure and dynamics of macromolecules.
Unlike X-ray crystallography or cryo-EM, NMR studies proteins in solution under conditions that closely resemble the physiological environment.
This aspect makes NMR ideal for investigating folded, intrinsically disordered, and highly dynamic proteins. It enables us to explore critical biological processes such as conformational changes, allosteric modulation, binding kinetics, and even monitor degradation in real time. Every project is tailored to your goals, but the foundation remains the same: rigorous science, transparent communication, and actionable results.
Protein-nmr process
While each project is unique, a typical workflow includes:
Summary of Our NMR Solutions
Our Protein Science and Structural Biology team offers advanced NMR to support three major aspects in research:
Protein Characterization in Solution
• Quality control under varying buffer conditions, with supplements, or after mutations
• Assessment of intramolecular interactions
• Stability over time, folding, and aggregation
• Suitable for unlabelled and labelled (15N and/or 13C) proteins
Fragment-Based Drug Discovery
• High-throughput fragment screening of either Ligand- or Protein-Observed NMR
• Cocktail-based library screening
• Hit identification, characterization, optimization and validation.
• Exploration of binders with wide range of affinities (nM, µM, mM)
• In-house data analysis for proteins and nucleic acids
• There is no size limitations for the protein being studied
•Suitable for labelled (15N- or 13C-Methyl) and unlabelled proteins
Protein Structure Determination
• Backbone and side-chain residue assignments
• Structure determination of proteins alone or in complex with partners
• Comprehensive in-house data analysis
Hear From One of our Experts
We provide a comprehensive NMR service, from construct design through to data collection and analysis. We have access to state-of-the-art, high-field NMR spectrometers. In addition, we have extensive experience in producing high-quality, uniformly labelled proteins using 15N, 13C and 2H isotopes. We can also perform residue-specific labelling if required (e.g.Methyl ( 13CH3-).
In this article we discuss the three techniques used for determining protein and nucleic acid…
Blog
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
From high -quality starting points to optimized leads, we unite fragment screening, structural biology, computational chemistry and medicinal chemistry to keep your program moving forward .
We not only provide a full gene to X-ray crystallography structure service but support your project with our insight and expertise, with a milestone-based approach.
